This is further supported by clinical efficacy data for antibodies to IL-33 and its receptor serum-stimulated 2 (ST2; also named IL1RL1 and IL1R4) that have provided clinical precedence for targeting IL-33 in chronic obstructive pulmonary disease (COPD) and asthma11–14. Here, IL33 is linked to chronic obstructive pulmonary disease.